Blossom covers the latest that goes on with psychedelic research. We make the waterfall of new papers easier to digest, for both laypeople, psychedelic entrepreneurs, and researchers alike. We provide handy overview posts every month and research highlights every second week.
Need an overview of where the research stands at this moment? Dive in with our Research Overview.
In October, natural language processing (NLP) was used to successfully predict clinical outcomes using data from a trial exploring psilocybin on treatment-resistant depression (TRD). The first real-world study assessing esketamine for TRD yielded positive results, while new evidence suggests people who microdose may build a tolerance which needs to be taken in future trials.
Everyone knows about MDMA for PTSD, but what if I told you there are 21 more areas psychedelics are being researched for?
Blossom‘s articles cover everything from the latest paper (also featured individually in our Papers Database) to analyses of research fields. From MDMA-AT for PTSD to psilocybin for TRD. We will pick apart the industry terms, e.g. MDMA-AT = MDMA-assisted therapy